Journal
BRITISH JOURNAL OF CANCER
Volume 111, Issue 9, Pages 1684-1687Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2014.108
Keywords
cancer clinical trials; socioeconomics
Categories
Funding
- Medical Research Council [MR/L006278/1] Funding Source: Medline
- Prostate Cancer UK [PA12-06] Funding Source: Medline
- Academy of Medical Sciences (AMS) [AMS-SGCL6-Papa] Funding Source: researchfish
- Medical Research Council [MR/L006278/1] Funding Source: researchfish
- National Institute for Health Research [CL-2011-17-007] Funding Source: researchfish
- Prostate Cancer UK [PA12-06] Funding Source: researchfish
- MRC [MR/L006278/1] Funding Source: UKRI
Ask authors/readers for more resources
Cancer clinical trials enable the development of novel agents for the potential benefit of cancer patients. Enrolment in a trial offers patients the chance of superior efficacy coupled to the risk of unanticipated toxicity. For trial results to be generalisable, the data need to be collected in patients' representative of the general cancer population. Socioeconomic deprivation is associated with poor cancer outcomes. In the developed world, the gap between the most and least deprived is widening. This mini-review explores the evidence regarding socioeconomics and access to cancer trials, highlighting the underrepresentation of deprived patients, and exploring reasons for this disparity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available